{
    "organizations": [],
    "uuid": "59669556d08067b86614e4a6587ffebdf2507b73",
    "author": "Charley Grant",
    "url": "https://www.wsj.com/articles/bristol-myers-has-farther-to-fall-1523893124",
    "ord_in_thread": 0,
    "title": "Bristol-Myers has Farther to Fall",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Bristol-Myers Squibb shareholders have a valuation problem.\nShares dove 8% Monday after the company unveiled mixed clinical data in a carefully watched trial for patients with lung cancer. Bristol-Myers announced its combination of immunotherapy drugs significantly reduced the risk of disease progression or death in a small subset of patients, but results were weaker in other arms of the trial.\n\nMixed...  ",
    "published": "2018-04-16T19:38:00.000+03:00",
    "crawled": "2018-04-17T02:45:51.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "squibb",
        "shareholder",
        "valuation",
        "problem",
        "share",
        "dove",
        "monday",
        "company",
        "unveiled",
        "mixed",
        "clinical",
        "data",
        "carefully",
        "watched",
        "trial",
        "patient",
        "lung",
        "cancer",
        "announced",
        "combination",
        "immunotherapy",
        "drug",
        "significantly",
        "reduced",
        "risk",
        "disease",
        "progression",
        "death",
        "small",
        "subset",
        "patient",
        "result",
        "weaker",
        "arm",
        "trial",
        "mixed"
    ]
}